Cargando…

Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients

In 2022, the antigenically divergent SARS-CoV-2 omicron variants (BA.1, BA.2, BA.4, BA.5) outcompeted previous variants and continued to cause substantial numbers of illnesses and deaths. We evaluated the safety and immunogenicity of the bivalent original/omicron BA.4/BA.5 Pfizer/BioNTech vaccine ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peled, Yael, Afek, Arnon, Patel, Jignesh K., Raanani, Ehud, Segev, Amit, Ram, Eilon, Fardman, Alexander, Beigel, Roy, Atari, Nofar, Kliker, Limor, Elkader, Bayan Abd, Mandelboim, Michal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society for Heart and Lung Transplantation. 2023
Materias:	ISHT Meeting
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112987/ https://www.ncbi.nlm.nih.gov/pubmed/37084801 http://dx.doi.org/10.1016/j.healun.2023.03.016

Ejemplares similares

Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022
por: Atari, Nofar, et al.
Publicado: (2022)

(8) 5th Dose Bivalent Omicron-Containing Booster Vaccine Against Covid-19 in Heart Transplant Recipients
por: Peled, Y., et al.
Publicado: (2023)

Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022–2023 Winter Season
por: Moss, Stephen, et al.
Publicado: (2023)

(7) Cellular and Humoral Responses to Vaccination Before or after SARS-CoV-2 Infection - Bridging the Knowledge Gap to End the Pandemic for Heart Transplant Recipients
por: Peled, Y., et al.
Publicado: (2023)

(6) BNT162b2-Vaccine-Induced Neutralization Responses are Immune Correlates of Clinical Protection Against SARS-CoV-2 in Heart Transplant Recipients
por: Peled, Y., et al.
Publicado: (2023)

COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022
por: Kliker, Limor, et al.
Publicado: (2022)

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant
por: Peled, Yael, et al.
Publicado: (2022)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up
por: Barda, Noam, et al.
Publicado: (2023)

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
por: Zou, Jing, et al.
Publicado: (2023)

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - Implications for the omicron variant: Correspondence
por: Peled, Yael, et al.
Publicado: (2022)

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial
por: Branche, Angela R., et al.
Publicado: (2023)

Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
por: Kopel, Hagit, et al.
Publicado: (2023)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
por: Peled, Yael, et al.
Publicado: (2021)

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Brève : Avis positif pour l’UE du rappel bivalent Omicron BA.4/BA.5
por: Dalmat, Yann-Mickael
Publicado: (2022)

Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study
por: Andersson, Niklas Worm, et al.
Publicado: (2023)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

Outbreak of Influenza and Other Respiratory Viruses in Hospitalized Patients Alongside the SARS-CoV-2 Pandemic
por: Fratty, Ilana S., et al.
Publicado: (2022)

Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern
por: Chaouat, Abigael E., et al.
Publicado: (2022)

Cocirculation of A(H3N2) and B/Victoria increased morbidity in hospitalized patients in the 2019–2020 A(H1N1)pdm09 predominant influenza season in Israel
por: Jurkowicz, Menucha, et al.
Publicado: (2023)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL
por: Benjamini, Ohad, et al.
Publicado: (2022)

Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
por: Arashiro, Takeshi, et al.
Publicado: (2023)

The predictive value of five glomerular filtration rate formulas for long‐term mortality in patients undergoing coronary artery bypass grafting
por: Ram, Eilon, et al.
Publicado: (2022)

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
por: Lustig, Yaniv, et al.
Publicado: (2021)

Immunogenicity of Bivalent Omicron BA.4/5–Adapted Vaccine in Hemodialysis Patients
por: Anft, Moritz, et al.
Publicado: (2023)

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
por: Carreño, Juan Manuel, et al.
Publicado: (2023)

Frailty and clinical outcomes following aortic valve replacement
por: Ram, Eilon, et al.
Publicado: (2022)

Revascularization outcomes in diabetic patients presenting with acute coronary syndrome with non-ST elevation
por: Ram, Eilon, et al.
Publicado: (2022)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Surgical treatment on infective endocarditis: impact of diabetes on mortality
por: Kogan, Alexander, et al.
Publicado: (2022)

Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern
por: Diem, Gabriel, et al.
Publicado: (2023)

To BaP or not to BaP? That is the question.
por: Goldstein, L S
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_6e5eeii9e5098kbmgd7ngnkfti